Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer: Results From BOLERO-2 (vol 34, pg 419, 2016)

被引：1
|
作者：
Hortobagyi, Gabriel N.
Chen, David
Piccart, Martine
Rugo, Hope S.
Burris, Howard A.
Pritchard, Kathleen I.
Campone, Mario
Noguchi, Shinzaburo
Perez, Alejandra T.
Deleu, Ines
Shtivelband, Mikhail
Masuda, Norikazu
Dakhil, Shaker
Anderson, Ian
Robinson, Douglas M.
He, Wei
Garg, Abhishek
McDonald, E. Robert, III
Bitter, Hans
Huang, Alan
Taran, Tetiana
Bachelot, Thomas
Lebrun, Fabienne
Lebwohl, David
Jose, Baselga
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期
关键词：
D O I：
10.1200/JCO.18.02265
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：355 / 355
页数：1
相关论文
共 50 条
  • [21] Efficacy of Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
    Qureshi, Zaheer
    Jamil, Abdur
    Fatima, Eeshal
    Altaf, Faryal
    Siddique, Rimsha
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2024, 47 (11): : 526 - 534
  • [22] Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2
    Noguchi, Shinzaburo
    Masuda, Norikazu
    Iwata, Hiroji
    Mukai, Hirofumi
    Horiguchi, Jun
    Puttawibul, Puttisak
    Srimuninnimit, Vichien
    Tokuda, Yutaka
    Kuroi, Katsumasa
    Iwase, Hirotaka
    Inaji, Hideo
    Ohsumi, Shozo
    Noh, Woo-Chul
    Nakayama, Takahiro
    Ohno, Shinji
    Rai, Yoshiaki
    Park, Byeong-Woo
    Panneerselvam, Ashok
    El-Hashimy, Mona
    Taran, Tetiana
    Sahmoud, Tarek
    Ito, Yoshinori
    BREAST CANCER, 2014, 21 (06) : 703 - 714
  • [23] BOLERO-2: Everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone receptor-positive breast cancer.
    Noguchi, Shinzaburo
    Masuda, Norikazu
    Ito, Yoshinori
    Iwata, Hiroji
    Mukai, Hirofumi
    Horiguchi, Jun
    Tokuda, Yutaka
    Kuroi, Katsumasa
    Iwase, Hirotaka
    Inaji, Hideo
    Ohsumi, Shozo
    Piccart-Gebhart, Martine J.
    Hortobagyi, Gabriel N.
    Rugo, Hope S.
    Gnant, Michael
    Campone, Mario
    Sahmoud, Tarek
    Pritchard, Kathleen I.
    Burris, Howard A.
    Baselga, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [24] Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2
    Shinzaburo Noguchi
    Norikazu Masuda
    Hiroji Iwata
    Hirofumi Mukai
    Jun Horiguchi
    Puttisak Puttawibul
    Vichien Srimuninnimit
    Yutaka Tokuda
    Katsumasa Kuroi
    Hirotaka Iwase
    Hideo Inaji
    Shozo Ohsumi
    Woo-Chul Noh
    Takahiro Nakayama
    Shinji Ohno
    Yoshiaki Rai
    Byeong-Woo Park
    Ashok Panneerselvam
    Mona El-Hashimy
    Tetiana Taran
    Tarek Sahmoud
    Yoshinori Ito
    Breast Cancer, 2014, 21 : 703 - 714
  • [25] Assessment of genetic alterations using next-generation sequencing in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the BOLERO-2 phase III trial
    Baselga, Jose
    Piccart, Martine
    Rugo, Hope
    Chen, David
    Burris, Howard A.
    Campone, Mario
    Noguchi, Shinzaburo
    Perez, Alejandra
    Deleu, Inas
    Shtivelband, Mikhail
    Provencher, Louise
    Derti, Adnan
    Huang, Alan
    McDonald, Rob
    Kalfoglou, Creton
    Robinson, Douglas
    Taran, Tetiana
    Sahmoud, Tarek
    Lebwohl, David
    Hortobagyi, Gabriel N.
    CANCER RESEARCH, 2013, 73 (08)
  • [26] Molecularly targeted therapy and immunotherapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer
    Song, Yuhua
    He, Lin
    Wang, Yaling
    Wu, Qian
    Huang, Wenzhi
    ONCOLOGY REPORTS, 2020, 44 (01) : 3 - 13
  • [27] Advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
    Shen, Le-Sang
    Jin, Xiao-Yan
    Wang, Xu-Meng
    Tou, Lai-Zhen
    Huang, Jian
    CHINESE MEDICAL JOURNAL, 2020, 133 (09) : 1099 - 1108
  • [28] The clinical benefit of epidermal growth factor receptor and human epidermal growth factor receptor 2 targeted agents adding to endocrine therapy in hormone receptor-positive breast cancer
    Li, Huan
    Zhai, Qing
    Yu, Bo
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2018, 14 : S218 - S223
  • [29] Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2
    Rugo, H. S.
    Pritchard, K. I.
    Gnant, M.
    Noguchi, S.
    Piccart, M.
    Hortobagyi, G.
    Baselga, J.
    Perez, A.
    Geberth, M.
    Csoszi, T.
    Chouinard, E.
    Srimuninnimit, V.
    Puttawibul, P.
    Eakle, J.
    Feng, W.
    Bauly, H.
    El-Hashimy, M.
    Taran, T.
    Burris, H. A., III
    ANNALS OF ONCOLOGY, 2014, 25 (04) : 808 - 815
  • [30] Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
    Rugo, Hope S.
    Bardia, Aditya
    Marme, Frederik
    Cortes, Javier
    Schmid, Peter
    Loirat, Delphine
    Tredan, Olivier
    Ciruelos, Eva
    Dalenc, Florence
    Pardo, Patricia Gomez
    Jhaveri, Komal L.
    Delaney, Rosemary
    Fu, Olivia
    Lin, Lanjia
    Verret, Wendy
    Tolaney, Sara M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (29) : 3365 - +
12345